Sustained DRSS improvement with aflibercept
October 16, 2019
Treating diabetic retinopathy (DR) with anti-vascular endothelial growth factor (VEGF) agents is an alternative to panretinal laser, and in some studies it has been found that “
Michelle Dalton, ELS
Several cyst characteristics linked to ischemia in DME
September 30, 2019
SWAP-TWO shows anatomic improvement after switch to aflibercept
September 17, 2019
For patients with diabetic macular edema (DME), intravitreal anti-vascular endothelial growth factor (VEGF) agents have become the first-line treatment.
Anti-VEGFs pose no additional risk of SAEs over other therapies
August 19, 2019
Anti-vascular endothelial growth factor (VEGF) therapy does not increase the risk of systemic serious adverse events in patients with diabetic macular edema (DME) compared with patients treated
Global trends show similar patterns worldwide
August 2, 2019
The ASRS Global Trends Survey finds differences in some treatment preferences
US, international physicians mostly in agreement over treatment practices
August 2, 2019
This year’s ASRS PAT survey show subtle regional differences
Anti-VEGF expansion treats all DR stages
June 14, 2019
An expanded indication for aflibercept injection (Eylea, Regeneron) is now approved by the FDA to treat all stages of diabetic retinopathy (DR).
Read-through, gene therapies for LCA showing promise
March 8, 2019
Group of researchers aim to validate both approaches in proof-of-concept study
Programs provide patient assistance for AMD treatments
February 26, 2019
Ongoing treatment with anti-vascular endothelial growth factor (VEGF) injections or photodynamic therapy (verteporfin) is, to date, the primary means of managing and treating AMD.
What’s in the wet AMD pipeline
February 26, 2019
With no “cure,” neovascular age-related macular degeneration (or wet AMD) remains a key disease state for numerous pharmaceutical companies.
